We will continue to adjust plans as required to support existing business and growth throughout our divisions. And for 2023, we expect Cash CapEx to be approximately $65,000,000 weighted towards expansion capital to support higher levels of activity and business development opportunity, particularly in the Production Chemicals division, as Ken mentioned. During Q3, we were very active in our NCIB purchasing 12,000,000 common shares at an average price of of $3.34 per share for a total of $40,000,000 Following Q3, we continued our aggressive buyback activity with an additional 2,900,000 common shares at an average price of $3.66 per share for a total of $10,400,000 We exited the quarter with a net draw on our senior facility of $92,200,000 compared to $120,200,000 at June 30 $208,500,000 at December 31, 2022. The decreases realized during the quarter were driven by strong cash flow generation enhanced by a reduction in required working capital Investments, partly offset by $40,000,000 in share repurchases and $6,300,000 in dividend payments. We ended Q3 with $454,000,000 in total debt, net of cash, comprised primarily of $288,000,000 in senior notes and a net draw in the senior facility of $92,200,000 Our total debt to adjusted EBITDAC declined to a prudent 1.46 times at the end of Q3, down steadily from 1.57 times at Q2 and 2.52 times a year ago, demonstrating our continued deleveraging trends.